{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:45:20Z","timestamp":1761947120399},"reference-count":43,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2002,1,2]],"date-time":"2002-01-02T00:00:00Z","timestamp":1009929600000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2000,12,27]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Empirical eradication therapy of <jats:italic>H. pylori<\/jats:italic> has been proposed as a therapeutic alternative for duodenal ulcer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim:<\/jats:title><jats:p>To identify the cost\u2010effectiveness of empirical eradication therapy vs. test\u2010and\u2010treatment for the management of patients already diagnosed with a duodenal ulcer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>A decision analysis was performed to compare the cost\u2010effectiveness of empirical eradication therapy of <jats:italic>H. pylori<\/jats:italic> diagnosed duodenal ulcer vs. eradication therapy after confirmatory diagnosis of <jats:italic>Helicobacter pylori<\/jats:italic> infection by means of several diagnostic tests.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>The empirical eradication therapy of duodenal ulcer was found to be the most effective and cost\u2010effective strategy of all the alternatives. Amongst the alternatives, which included the previous performance of confirmatory diagnostic tests, the best cost\u2010effectiveness ratio used a serology test. The model was robust in the face of changes in the values of therapeutic effectiveness, sensitivity and specificity of the diagnostic tests, prevalence of <jats:italic>H. pylori<\/jats:italic> infection in duodenal ulcer, duration of the antisecretory therapy, and number of medical visits.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Based on our cost\u2010effectiveness analysis, a treat approach is more effective and cost\u2010effective than a test\u2010and\u2010treat approach in the clinical management of already diagnosed duodenal ulcer.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2000.00871.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:40:37Z","timestamp":1047354037000},"page":"1631-1638","source":"Crossref","is-referenced-by-count":8,"title":["Management of <i>Helicobacter pylori<\/i> in duodenal ulcer: a cost\u2010effectiveness analysis"],"prefix":"10.1111","volume":"14","author":[{"given":"A.","family":"Garc\u00eda\u2010Alt\u00e9s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. J.","family":"Jovell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Serra\u2010Prat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Aymerich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,2]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.145321000.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-201204001-00006"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.71.837.413"},{"key":"e_1_2_6_5_2","first-page":"1311","article-title":"Unidentified curved bacili in the stomach of patients with gastritis and peptic ulceration","author":"Marshall BJ","year":"1983","journal-title":"Lancet"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0953-0673.1996.00251.x"},{"key":"e_1_2_6_7_2","first-page":"753","article-title":"The role of H. pylori eradication in the management of acute bleeding peptic ulcer","volume":"7","author":"McColl KEL","year":"1995","journal-title":"European J Gastroenterol Hepatol"},{"key":"e_1_2_6_8_2","first-page":"189","article-title":"Indications for treatment of Helicobacter pylori infection: a systematic overview","volume":"150","author":"Veldhuyzen Zanten SJO","year":"1994","journal-title":"Can Med Assoc J"},{"key":"e_1_2_6_9_2","first-page":"197","article-title":"Anuario de la sanidad y del medicamento en Espa\u00f1a, 1997","volume":"636","author":"Farmaindustria","year":"1997","journal-title":"El M\u00e9dico"},{"key":"e_1_2_6_10_2","unstructured":"JovellAJ AymerichM Garc\u00eda\u2010Alt\u00e9sA&Serra\u2010PratM.Guia de pr\u00e0ctica cl\u00ednica del tractament eradicador de la infecci\u00f3 perHelicobacter Pyloriassociada a \u00falcera duodenal en l\u2019atenci\u00f3 prim\u00e0ria. Barcelona: Ag\u00e8ncia d\u2019Avaluaci\u00f3 de Tecnologia M\u00e8dica. Servei Catal\u00e0 de la Salut. Departament de Sanitat i Seguretat Social. Generalitat de Catalunya 1998."},{"key":"e_1_2_6_11_2","unstructured":"Scottish Intercollegiate Guidelines Network.Helicobacter pylori. Eradication in Dyspeptic Disease. Edinburgh: SIGN 1996."},{"key":"e_1_2_6_12_2","unstructured":"Scottish Health Purchasing Information Center. Dyspepsia Peptic Ulcer andHelicobacter pylori. Aberdeen: SHPIC 1996."},{"key":"e_1_2_6_13_2","first-page":"1","article-title":"Nuevas terapias triples de una semana de duraci\u00f3n con metronidazol para la erradicaci\u00f3n de Helicobacter pylori: claritromicina o amoxicilina como segundo antibi\u00f3tico","volume":"110","author":"Gisbert JP","year":"1998","journal-title":"Med Cl\u00ednica (Bar)"},{"key":"e_1_2_6_14_2","unstructured":"Veldhuyzen ZantenSJO BradetteM&FarleyA et\u2003al.The Du\u2010mach study: Eradication ofHelicobacter pylori ulcer healing and relapse in duodenal ulcer patients. Omeprazole and clarithromycin in combination with either amoxicillin or metronidazole.Gut1997."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.1996.tb00027.x"},{"key":"e_1_2_6_16_2","first-page":"A229","article-title":"Omeprazole\u2010based dual and triple therapy for the eradication of H. pylori infection in peptic ulcer disease","volume":"110","author":"Pieramico O","year":"1996","journal-title":"Gastroenterology"},{"key":"e_1_2_6_17_2","first-page":"221","article-title":"One week treatment with omeprazole, clarithromycin and tinidazole or lansoprazole, amoxicillin and metronidazole for cure of Helicobacter pylori infection in duodenal ulcer patients","volume":"47","author":"Sito E","year":"1996","journal-title":"J Physiol Pharmacol"},{"key":"e_1_2_6_18_2","first-page":"718","article-title":"Impact of colloidal bismuth subnitrate in the eradication rates of Helicobacter pylori infection\u2010associated duodenal ulcer using a short treatment regimen with omeprazole and clarithromycin: a randomized study","volume":"90","author":"Forn\u00e9 M","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_19_2","first-page":"S45","article-title":"Combination therapy with mucosal protective agent for the eradication of Helicobacter pylori","volume":"7","author":"Fukuda Y","year":"1995","journal-title":"European J Gastroenterol Hepatol"},{"key":"e_1_2_6_20_2","first-page":"59","article-title":"The prevalence of Helicobacter pylori in peptic ulcer disease","volume":"9","author":"Kuipers EJ","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"e_1_2_6_21_2","first-page":"311","article-title":"Prevalencia del Helicobacter pylori en patolog\u00eda g\u00e1strica en Arag\u00f3n","volume":"82","author":"Mur M","year":"1992","journal-title":"Revista Espa\u00f1ola Enfermedades Digestivas"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.1999.02005.x"},{"key":"e_1_2_6_23_2","first-page":"15\u2003082","article-title":"Ordre del 23 de desembre de 1997, per la qual es fixen per a l\u2019any 1997 els valors de les unitats de pagament per a la contraprestaci\u00f3 de la realitzaci\u00f3 de proves de suport diagn\u00f2stiques practicades pels centres hospitalaris per a malalts aguts en r\u00e8gim de concert amb el Servei Catal\u00e0 de la Salut","volume":"2547","author":"DOGC","year":"1997","journal-title":"Diari Oficial de la Generalitat de Catalunya"},{"key":"e_1_2_6_24_2","first-page":"12\u2003149","article-title":"Ordre del 29 de setembre de 1997, per la qual s\u2019aproven els preus p\u00fablics corresponents als serveis que presta l\u2019Institut Catal\u00e0 de la Salut","volume":"2504","author":"DOGC","year":"1997","journal-title":"Diari Oficial de la Generalitat de Catalunya"},{"key":"e_1_2_6_25_2","unstructured":"Vademecum Internacional. Especialidades Farmac\u00e9uticas Y Biol\u00f3gicas Productos Y Art\u00edculos de Farmacia M\u00e9todos de Diagn\u00f3stico 38thedition. Madrid: Medicom S.A. 1997."},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.15.1651"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-9-199511010-00004"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7145.1648"},{"key":"e_1_2_6_29_2","first-page":"545","article-title":"Evaluation of the dyspeptic patient: a cost\u2010utility study","volume":"44","author":"Ebell MH","year":"1997","journal-title":"J Family Prac"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-4-199702150-00004"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529309098356"},{"key":"e_1_2_6_32_2","unstructured":"AymerichM Garc\u00eda\u2010Alt\u00e9sA&JovellAJ.Revisi\u00f3 de l\u2019evid\u00e8ncia cient\u00edfica de les implicacions cl\u00edniques i econ\u00f2miques de la resist\u00e8ncia bacteriana a la vancomicina. Barcelona: Ag\u00e8ncia d\u2019Avaluaci\u00f3 de Tecnologia M\u00e8dica. Servei Catal\u00e0 de la Salut. Departament de Sanitat i Seguretat Social. Generalitat de Catalunya gener1998."},{"key":"e_1_2_6_33_2","first-page":"553","article-title":"Las resistencia bacterianas: algo m\u00e1s que un problema cl\u00ednico? La resistencia del enterococo a la vancomicina como ejemplo","volume":"112","author":"Aymerich M","year":"1999","journal-title":"Med Cl\u00ednica (Bar)"},{"key":"e_1_2_6_34_2","unstructured":"P\u00e9rez MotaA.Helicobacter pyloriY Patolog\u00eda G\u00e1strica.1997."},{"key":"e_1_2_6_35_2","first-page":"2125","article-title":"Diagnostic tests for Helicobacter pylori: a prospective evaluation of their accurancy, without selecting a single test as the gold standard","volume":"91","author":"Thijs JC","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.31.11.1237"},{"key":"e_1_2_6_37_2","first-page":"438","article-title":"A 20 minutes breath test for Helicobacter pylori","volume":"86","author":"Marshall BJ","year":"1991","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_38_2","first-page":"1940","article-title":"Validation of a simplified carbon\u201014\u2010urea breath test for routine use for detection of Helicobacter pylori noninvasively","volume":"31","author":"Henze E","year":"1990","journal-title":"J Nuclear Med"},{"key":"e_1_2_6_39_2","first-page":"1138","article-title":"Do commercial serological kits for Helicobacter pylori infection differ in accurancy? A meta\u2010analysis","volume":"91","author":"Loy CT","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.32.7.1663-1668.1994"},{"key":"e_1_2_6_41_2","first-page":"561","article-title":"Diagn\u00f3stico de la infecci\u00f3n por Campylobacter pylori en la mucosa g\u00e1strica: aspectos histol\u00f3gicos y microbiol\u00f3gicos","volume":"94","author":"Sainz S","year":"1990","journal-title":"Med Cl\u00ednica"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.42.7.727"},{"key":"e_1_2_6_43_2","first-page":"133","article-title":"Usefulness of culture, histology and urease testing in the detection of Campylobacter pylori","volume":"84","author":"Schnell GA","year":"1989","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.32.5.467"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2000.00871.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2000.00871.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2000.00871.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T09:56:44Z","timestamp":1698573404000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2000.00871.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12,27]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2000,12,27]]}},"alternative-id":["10.1046\/j.1365-2036.2000.00871.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2000.00871.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,12,27]]}}}